Related Experiment Video
Updated: Jan 16, 2026
10:18
Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
17.5K
Novel pH-Responsive PSS-Loaded Chitosan Matrix Nanoparticles Ameliorate Pressure Overload-Induced Cardiac Hypertrophy
Meijie Xu1,2, Zhen Fan1, Dingfu Wang1,2
1Key Laboratory of Marine Drugs of the Ministry of Education, Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Marine Drugs
|September 26, 2025
Summary
This study developed pH-responsive nanoparticles for propylene glycol alginate sulfate sodium (PSS), a marine drug, improving cardiac hypertrophy treatment. The novel PSS nanoparticles demonstrated enhanced cardioprotective effects in preclinical models.
Area of Science:
- Cardiovascular Research
- Nanomedicine
- Drug Delivery Systems
Background:
- Cardiac hypertrophy is a major cause of heart failure with limited therapeutic options.
- Propylene glycol alginate sulfate sodium (PSS), a marine sulfated polysaccharide, shows promise for cardiovascular diseases.
- Novel drug delivery systems are needed to enhance PSS efficacy and therapeutic potential.
Purpose of the Study:
- To design and characterize a pH-responsive nanoparticle system for PSS delivery.
- To evaluate the in vitro and in vivo efficacy of PSS-loaded nanoparticles in ameliorating cardiac hypertrophy.
- To explore the integration of pH-responsiveness and bile acid transport for enhanced PSS delivery.
Main Methods:
- Fabrication of PSS-loaded nanoparticles using trimethyl chitosan glycocholic acid (TMC-GA) and Hydroxypropyl methylcellulose phthalate (HP55).
- Characterization of nanoparticle size, zeta potential, and encapsulation efficiency.
- In vitro release studies to assess pH-responsiveness and intestinal absorption.
- In vitro assessment of PSS biocompatibility and effect on myocardial hypertrophy.
- In vivo evaluation of nanoparticle efficacy in a mouse model of pressure overload-induced cardiac hypertrophy.
Main Results:
- TMC-GA/HP55@PSS nanoparticles were successfully prepared with favorable characteristics (361.5 nm size, -30.3 mV zeta potential, 92.52% EE).
- The nanoparticles exhibited pH-responsive release and enhanced intestinal absorption.
- In vitro studies confirmed PSS biocompatibility and its ability to mitigate myocardial hypertrophy.
- In vivo studies showed significant amelioration of cardiac hypertrophy by PSS nanoparticles, with TMC-GA/HP55@PSS demonstrating superior efficacy.
Conclusions:
- The developed pH-responsive PSS nanoparticles represent a novel and effective drug delivery system for treating cardiac hypertrophy.
- Integration of pH-responsiveness and bile acid transport enhances PSS delivery and cardioprotective effects.
- This formulation offers a promising strategy for expanding the clinical applications of PSS in cardiovascular medicine.
